株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオシミラーモノクロナール抗体 (mAb) の世界市場予測 2018-2028年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab のバイオシミラー

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

発行 Visiongain Ltd 商品コード 275993
出版日 ページ情報 英文 204 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=149.86円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオシミラーモノクロナール抗体 (mAb) の世界市場予測 2018-2028年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab のバイオシミラー Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
出版日: 2018年02月27日 ページ情報: 英文 204 Pages
概要

世界のバイオシミラーモノクローナル抗体(mAb)市場は、2018年から2028年の調査期間に19%のCAGR(年間複合成長率)で推移し、2023年までに59億米ドル規模に達することが予測されています。

当レポートでは、世界のバイオシミラーモノクロナール抗体 (mAb) 市場について調査し、市場予測、2次市場別の収益予測、上市・開発中のバイオシミラー抗体別の収益予測、主要国市場の分析と予測、STEP分析および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 レポート概要

第2章 イントロダクション:バイオシミラーモノクロナール抗体

  • 自然抗体:免疫システムの鍵
  • 血清療法からモノクロナール抗体 (mAbs) へ
  • mAbヒト化
  • 生物製剤とバイオシミラー
  • バイオシミラーの需要が高いのはなぜか?
  • バイオシミラー開発の検討事項
  • 既に上市されているバイオシミラーモノクロナール抗体

第3章 バイオシミラーモノクロナール抗体の世界市場予測

  • 現在の世界におけるバイオシミラーモノクロナール抗体市場
  • 世界のバイオシミラーmAb市場:収益予測
  • 世界のバイオシミラーmAb市場‐化合物別:収益・市場シェア予測
  • 世界のバイオシミラーmAb市場‐化合物別:収益予測
  • バイオシミラーmAb市場の成長促進因子・抑制因子
  • バイオシミラーmAb市場の成長抑制因子

第4章 各バイオシミラーmAb製品:上市薬・パイプライン薬

  • 上市されているバイオシミラーmAb
  • パイプラインバイオシミラー

第5章 主要国のバイオシミラーモノクロナール抗体市場

  • 主要国市場のバイオシミラーmAb状況は?
  • 主要国市場のシェアは予測期間を通してどう変化するか?
  • インド:バイオシミラーmAbで現在首位となっているが成長は減速する見通し
  • ロシア:規制の枠組みの欠如が短期的にはうまくいく
  • 韓国:市場は早期のバイオシミラーガイドラインから恩恵を受ける
  • 中国:細分化したバイオシミラーmAb市場
  • ブラジル:ANVISAのバイオシミラー規制はEMAと類似
  • EUにおけるバイオシミラーmAbの展望
  • 日本におけるバイオシミラーmAbの展望
  • 米国におけるバイオシミラーmAbの展望

第6章 主要企業

  • バイオシミラーmAb開発におけるコラボレーション
  • BioXpress
  • Celltrion
  • Harvest Moon
  • Genor Biopharma
  • Samsung Bioepsis
  • Mabion
  • Gene Techno Science
  • インドのBiocon
  • Coherus Biosciences
  • BIOCAD
  • 大手企業とバイオシミラーmAb市場

第7章 バイオシミラーモノクロナール抗体市場の定性的分析

  • 強みと弱み
  • 機会と脅威
  • バイオシミラーmAb市場に影響を及ぼす社会、技術、経済および政治的要因 (STEP分析)

第8章 結論

  • バイオシミラーモノクロナール抗体:世界市場
  • 市場・パイプラインにおける化合物の将来
  • 主要国市場
  • 主要企業
  • 産業動向の現状・予測

付録

目次
Product Code: PHA0288

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 74 figures- all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilar Monoclonal Antibodies Market forecasts from 2018-2028
  • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab

image1

  • This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
  • Remsima/Inflectra
  • Infimab
  • Reditux
  • BI695500
  • CT-P10
  • BI695501
  • FKB327
  • FKB238
  • Mabtas
  • AcellBia
  • Maball
  • Clotinab
  • Abcixirel
  • BCD-022
  • BCD-021
  • Herzuma
  • CANMAB/Hertraz
  • Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
  • The US Biosimilar mAb Market
  • Japanese Biosimilar mAb Market
  • EU5 Biosimilar mAb Markets
  • BRIC and South Korea Biosimilar mAb Markets
  • Rest of the World Biosimilar mAb Market

This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
  • 1.2 Why You Should Read this Report
  • 1.3 How This Study Delivers
  • 1.4 Main Questions Answered by the Analysis
  • 1.5 Who is This Investigation For?
  • 1.6 Method of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated visiongain Reports
  • 1.9 About visiongain

2. Introduction to Biosimilar Monoclonal Antibodies

  • 2.1 Natural Antibodies: Key to the Immune System
  • 2.2 From Serum therapy to Monoclonal Antibodies
  • 2.3 Humanising the mAb
  • 2.4 Biologics (Biological Drugs) and Biosimilars
  • 2.5 Why are Biosimilars in High Demand?
  • 2.6 Considerations for the Development of Biosimilars
    • 2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
    • 2.6.2 How Much of a Concern is Immunogenicity?
  • 2.7 Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2018-2028

  • 3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
  • 3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2028
  • 3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2023 and 2028
  • 3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2028
    • 3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
    • 3.4.2 Biosimilar Infliximab
    • 3.4.3 Biosimilar Rituximab
    • 3.4.4 Biosimilar Abciximab
    • 3.4.5 Biosimilar Trastuzumab
    • 3.4.6 Biosimilar Adalimumab
    • 3.4.7 Biosimilar Bevacizumab
  • 3.5 Drivers and Restraints for the Biosimilar mAb market 2018-2028
    • 3.5.1 Driving Factors of the Biosimilar mAb Market 2018-2028
  • 3.6 Restraining Factors of the Biosimilar mAb Market 2018-2028

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2018-2028

  • 4.1 Biosimilar mAbs on the Market in 2017
    • 4.1.1 Celltrion's Remsima/ Hospira's Inflectra/ Egis' Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
    • 4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
    • 4.1.3 Dr Reddy's Reditux (Rituximab): No Application for EU or US Approval
    • 4.1.4 Intas Pharmaceuticals' Mabtas (Rituximab)
    • 4.1.5 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
    • 4.1.6 MABALL: Faces Competition from other Biosimilar Rituximabs in India
    • 4.1.7 Isu Abxis' Clotinab (abciximab):
    • 4.1.8 AbcixiRel: The First Indian Abciximab Biosimilar
    • 4.1.9 Herzuma (Trastuzumab): Approved in South Korea
    • 4.1.10 CANMAb/Hertraz (Trastuzumab)
  • 4.2 Pipeline Biosimilars
    • 4.2.1 BI695500 (Rituximab)
    • 4.2.2 CT-P10 (Rituximab): Celltrion's Reputation for Biosimilars will Assist Sales
    • 4.2.3 Boehringer Ingelheim's BI695501 (Adalimumab)
    • 4.2.4 BCD-022 (Trastuzumab): Approved in Russia
    • 4.2.5 Fujifilm Kyowa Kirin Biologics' FKB327 (Adalimumab)
    • 4.2.6 Fujifilm Kyowa Kirin Biologics' FKB238 (Bevacizumab)
    • 4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue

5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2018-2028

  • 5.1 What Were the Leading National Markets for Biosimilar mAbs in 2017?
  • 5.2 How Will National Market Shares Change Over the Forecast Period?
  • 5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth Will Slow
    • 5.3.1 India Releases New Biosimilar Development Guidelines
    • 5.3.2 Indian Biosimilar Submarket Forecast 2016-2028
  • 5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 5.4.1 Russian Government Backed 'Pharma 2020' Initiative
    • 5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.4 South Korean Market Has Benefitted from Early Biosimilar Guidelines
    • 5.4.1 Significant Investment in Biosimilars in South Korea
    • 5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.5 China: A Fragmented Biosimilar mAb Market
    • 5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2017
    • 5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.6 Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2028
  • 5.7 The Outlook for Biosimilar mAbs in the EU 2016-2028
    • 5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
    • 5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2028
    • 5.7.3 Germany: The Current EU Leader
    • 5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
    • 5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
    • 5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
    • 5.7.7 Spain: High Biosimilar mAb Discounts Expected
  • 5.8 The Outlook for Biosimilar mAbs in Japan
    • 5.8.1 Regulations for Naming Biosimilars
    • 5.8.2 Biosimilar mAb Market Activity in Japan
    • 5.8.3 Japanese Biosimilar Submarket Forecast 2016-2028
  • 5.9 US Biosimilar mAb Outlook: None Currently on the Market
    • 5.9.1 US FDA Biosimilar Guidelines were Released in 2015
    • 5.9.2 Legal Challenges for Biosimilars in the US
    • 5.9.3 State Regulation of Biosimilar Substitution
    • 5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2016-2028
    • 5.9.5 The Mexico Biosimilar mAb Market Revenue Forecast, 2016-2028
    • 5.9.6 The Canada Biosimilar mAb Market Revenue Forecast, 2016-2028

6. Leading Companies in the Biosimilar Monoclonal Antibodies Market

  • 6.1 Collaboration in Biosimilar mAb Development
  • 6.2 BioXpress
  • 6.3 Celltrion
  • 6.4 Harvest Moon
  • 6.5 Genor Biopharma
  • 6.6 Samsung Bioepsis
  • 6.7 Mabion
  • 6.8 Gene Techno Science
  • 6.9 India's Biocon
  • 6.10 Coherus Biosciences
  • 6.11 BIOCAD
  • 6.12 Big Pharma and the Biosimilar mAb Market

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies Market

  • 7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibodies Market, 2016-2028
    • 7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
    • 7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
    • 7.1.3 Approval Pathways are Now Established in Developed Markets
    • 7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
    • 7.1.5 Doctor and Patient Confidence May Take Time
  • 7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibodies Market, 2016-2028
    • 7.2.1 Market Opportunities from Patent Expiries and a Well-Stocked Pipeline
    • 7.2.2 Substitution may Not Occur Automatically
    • 7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
  • 7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2028
    • 7.3.1 Social Factors: Driving or Restraining the Market?
    • 7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
    • 7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
    • 7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry

8. Conclusions

  • 8.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2028
  • 8.2 Future of Compounds on the Market and in the Pipeline
  • 8.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2017, 2023, 2028
  • 8.4 Leading Companies in the Biosimilar mAb Market
  • 8.5 Current and Expected Industry Trends 2016-2028
    • 8.5.1 Cost Control of Healthcare Will Work in Favour mAbs
    • 8.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
    • 8.5.3 Complex Production Processes are a Restraining Factor
    • 8.5.4 Clinician and Patient Confidence Must be Maximized to Ensure Uptake
    • 8.5.5 Biobetters Pose a Threat

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Classification of Monoclonal Antibodies
  • Table 2.2 Murine Monoclonal Antibodies on the Market
  • Table 2.3 Chimeric Monoclonal Antibodies on the Market
  • Table 2.4 Humanised Monoclonal Antibodies on the Market
  • Table 2.5 Fully Human Monoclonal Antibodies on the Market
  • Table 2.6 Revenue of Originator Monoclonal Antibody Products in 2016
  • Table 3.1 Global Biosimilar mAbs Market Forecast 2016-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.2 Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2017, 2023 and 2028
  • Table 3.3 EU and US Patent Expiry Dates for the Main mAb Reference Products
  • Table 3.4 Global Biosimilar mAbs Market Forecast by Reference Compound: Revenue ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.5 Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
  • Table 3.6 Global Biosimilar Infliximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.7 Biosimilar Rituximab: Compounds (Marketed or in the Pipeline), 2018
  • Table 3.8 Global Biosimilar Rituximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.9 Biosimilar Abciximab: Compounds (Marketed or in the Pipeline), 2018
  • Table 3.10 Global Biosimilar Abciximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.11 Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2018
  • Table 3.12 Global Biosimilar Trastuzumab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.13 Biosimilar Adalimumab: Compounds (Marketed or in the Pipeline) 2018
  • Table 3.14 Global Biosimilar Adalimumab Market Forecast 2016-2028: Revenue ($m), AGR (%), and CAGR (%)
  • Table 3.15 Biosimilar Bevacizumab: Compounds (Marketed or in the Pipeline) 2018
  • Table 3.16 Global Biosimilar Bevacizumab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 4.1 Biosimilar mAbs on the Market in 2017: Revenues ($m) and Market Shares (%)
  • Table 4.2 Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.3 Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.4 Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5 Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.6 Biocad Distribution Partners for AcellBia, 2017
  • Table 4.7 AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.8 MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.9 Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.10 AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.11 Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.12 CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.13 BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.14 CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2027
  • Table 4.15 BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2028
  • Table 4.16 BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.17 FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2028
  • Table 4.18 FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2020-2028
  • Table 4.19 BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2028
  • Table 5.1 Leading National Markets for the Global Biosimilar mAb Industry, 2017
  • Table 5.2 Leading National Markets for the Global Biosimilar mAb Industry, 2017, 2023, 2028
  • Table 5.3 The Indian Biosimilar Mab Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.4 The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.5 The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.6 The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.7 The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.8 The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Table 5.9 The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.10 The French Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.11 The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.12 The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.13 The Spanish Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.14 The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.15 Finalised FDA Biosimilar Guidelines, 2015
  • Table 5.16 The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 5.17 The Mexico Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 5.17 The Canada Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 6.1 Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2017
  • Table 6.2 Selected Collaborations for Biosimilar mAb Development, 2009-2017
  • Table 6.3 BioXpress: Compounds in the Pipeline, 2018
  • Table 6.4 Tests Carried Out by BioXpress During Biosimilar mAb Development, with Objectives
  • Table 6.5 Compounds in Celltrion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2017
  • Table 6.6 Genor Biopharma: Biosimilar mAbs Pipeline, 2017
  • Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2017
  • Table 6.8 Gene Techno Science: Revenue ($m), from 2013-2017
  • Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2017
  • Table 6.10 Big Pharma's Positions in the Biosimilar mAb Industry, 2017
  • Table 7.1 Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2028
  • Table 7.2 Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2028
  • Table 7.3 Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2028

List of Figures

  • Figure 1.1 Main Compound Classes of Biosimilar mAbs, 2018
  • Figure 2.1 Structure of an Antibody
  • Figure 3.1 Global Biosimilar mAbs Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.2 The Biosimilar mAb Market: Market Share (%) by compound in 2017
  • Figure 3.3 The Biosimilar mAb Market: Market Share (%) by compound in 2023
  • Figure 3.4 The Biosimilar mAb Market: Market Share (%) by compound in 2028
  • Figure 3.5 Global Biosimilar Infliximab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.6 Global Biosimilar Rituximab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.7 Global Biosimilar Abciximab Market Forecast: Revenue ($m), AGR (%), and CAGR (%)
  • Figure 3.8 Global Biosimilar Trastuzumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.9 Global Biosimilar Adalimumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.10 Global Biosimilar Bevacizumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.11 Drivers and Restraints for the Global Biosimilar mAb market 2016-2028
  • Figure 4.1 Biosimilar mAb Versions on the Market: Market Share (%) 2017
  • Figure 4.2 Biosimilar mAb Versions on the Market: Market Share (%) 2023
  • Figure 4.3 Biosimilar mAb Versions on the Market: Market Share (%) 2028
  • Figure 4.4 Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2028
  • Figure 4.5 Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2028
  • Figure 4.6 Infimab (Infliximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.7 Infimab (Infliximab): AGR Forecast (%) 2016-2028
  • Figure 4.8 Reditux (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.9 Reditux (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.10 Mabtas (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.11 Mabtas (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.12 AcellBia (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.13 AcellBia (Rituximab): AGR Forecast(%) 2016-2028
  • Figure 4.14 MABALL (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.15 MABALL (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.16 Clotinab (Abciximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.17 Clotinab (Abciximab): AGR Forecast (%) 2016-2028
  • Figure 4.18 AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.19 AbcixiRel (Abciximab): AGR Forecast (%) 2016-2028
  • Figure 4.20 Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.21 Herzuma (Trastuzumab): AGR Forecast (%) 2016-2028
  • Figure 4.22 CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.23 CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2028
  • Figure 4.24 BI695500 (Rituximab): Revenue Forecast ($m) 2018-2028
  • Figure 4.25 BI695500 (Rituximab): AGR Forecast (%) 2019-2028
  • Figure 4.26 CT-P10 (Rituximab): Revenue Forecast ($m) 2019-2028
  • Figure 4.27 CT-P10 (Rituximab): AGR Forecast (%) 2019-2028
  • Figure 4.28 BI695501 (Adalimumab): Revenue Forecast ($m) 2018-2028
  • Figure 4.29 BI695501 (Adalimumab): AGR Forecast (%) 2019-2028
  • Figure 4.30 BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.31 BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2028
  • Figure 4.32 FKB327 (Adalimumab): Revenue Forecast (%) 2018-2028
  • Figure 4.33 FKB327 (Adalimumab): AGR Forecast (%) 2019-2028
  • Figure 4.34 FKB238 (Adalimumab): Revenue Forecast ($m) 2020-2028
  • Figure 4.35 FKB238 (Adalimumab): AGR Forecast (%) 2022-2028
  • Figure 4.36 BCD-021 (Bevacizumab): Revenue Forecast ($m) 2017-2028
  • Figure 4.37 BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2028
  • Figure 5.1 The Biosimilar Mab Market by Country: Market Shares (%) of Revenue, 2017
  • Figure 5.2 The Biosimilar Mab Market: National Submarket Shares (%), 2023
  • Figure 5.3 The Biosimilar Mab Market: National Submarket Shares (%), 2028
  • Figure 5.4 The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.5 The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.6 The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.7 The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.8 The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.9 The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2028
  • Figure 5.10 The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2028
  • Figure 5.11 The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.12 The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.13 The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.14 The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.15 The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.16 The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.17 Biosimilar mAbs in the US: Revenue Forecast ($m), 2017-2028
  • Figure 5.18 Biosimilar mAbs in the Mexico: Revenue Forecast ($m), 2016-2028
  • Figure 5.19 Biosimilar mAbs in the Canada: Revenue Forecast ($m), 2016-2028
  • Figure 6.1 Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline (2017)
  • Figure 8.1 Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2017, 2023 and 2028
  • Figure 8.2 Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2017, 2023 and 2028
  • Figure 8.3 Leading National Markets: Revenues ($m), 2017, 2023 and 2028
  • Figure 8.4 Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2017

Companies Listed

  • Abbott
  • AbbVie
  • Aché
  • Actavis
  • AET BioTech
  • Alexion Pharmaceuticals
  • Allergan
  • Alvogen
  • Alvotech
  • Amgen
  • Apotex
  • Aprogen
  • Array Bridge
  • AstraZeneca
  • Aurobindo Pharma Limited
  • Axis Biotec Brasil
  • Baliopharm GmbH
  • Baxalta
  • Bayer
  • Binex
  • BIO
  • Bio Farma
  • BIOCAD
  • Biocerus
  • Biocon
  • Biogen Idec
  • Bio-Manguinhos
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Cell Therapeutics
  • Celltrion
  • Celon Pharma Łomianki
  • Chugai
  • CinnaGen
  • CinnaGen
  • Coherus BioSciences
  • Daiichi Sankyo
  • DM Bio
  • Dong-A Pharma
  • Dr Reddy's
  • Dyadic International, Inc.
  • Egis Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Emcure
  • EMS
  • Epirus Biopharmaceuticals
  • Farmasa
  • Fresenius
  • Fujifilm
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Genentech
  • GeneTechno Science
  • Genexo
  • Genor Biopharma
  • GlaxoSmithKline
  • Glycotope
  • Hanwha Chemical
  • Harvest Moon
  • Hetero Group
  • Hospira
  • Hypermarcas
  • iBio
  • IBSS Biomed
  • ImClone LLC
  • Instas Pharmaceuticals
  • Instituto Vital Brazil
  • Intas Biopharmaceuticals
  • IPCA Labs
  • Isu Abxis
  • Janssen
  • JHL Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorio Elea
  • Laboratorios Liomont
  • LG Life Sciences
  • Lonza
  • Mabion
  • Mabtech Limited
  • mAbxience
  • MedImmune
  • Merck & Co.
  • Merck (MSD)
  • Merck Serono
  • Millhouse LLC
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Momenta Pharmaceuticals
  • Mustafa Nevzat Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Co.
  • Nippon Kayaku
  • Novartis
  • Oncobiologics
  • Otsuka Pharmaceutical
  • Parexel
  • Paul-Ehrlich Institute of Germany
  • Pfizer
  • PharmaPraxis
  • Pharmstandard
  • PhRMA
  • PlantForm
  • Polfarmex
  • ProBioGen
  • Probiomed
  • QuantiaMD
  • Quintiles
  • Ranbaxy Laboratories
  • Regeneron Pharmaceuticals
  • Reliance GeneMedix
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis
  • Samsung Biologics
  • Sandoz
  • Sanofi
  • Schnell
  • Seattle Genetics
  • Shanghai CP Guojian
  • Shionogi
  • Sorrento Therapeutics
  • Spectrum Pharmaceuticals
  • Stada Arzneimittell AG
  • Synthon
  • Takeda
  • Teva Pharmaceutical
  • TL Biopharmaceutical AG
  • UCB
  • União Química
  • Viropro
  • Walvax Biotechnology
  • Wyeth
  • Zenotech Laboratories
  • Zhejiang HISUN Pharmaceuticals Co. Ltd. (HISUN)
  • Zhejiang Huahai Pharmaceutical
  • Zydus-Cadila

List of Organizations Mentioned in the Report

  • Agence française de sécurité sanitaire des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Central Drugs Standard Control Organisation and the Department of Biotechnology
  • Chinese Centre for Drug Evaluation (CDE)
  • Cour des Comptes (France)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fraunhofer Center for Molecular Biology
  • Health Canada
  • India Brand Equity Foundation
  • Israel Institute for Biological Research (IIBR)
  • Korean Food and Drug Administration (KFDA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Food and Drug Safety (South Korea)
  • Ministry of Health of the Russian Federation
  • Ministry of Health, Labour and Welfare (MHLW)
  • National Institute for Health and Care Excellence (NICE)
  • National Institute for Health Research Horizon Scanning Centre
  • Norwegian Medical Agency
  • Scientific Centre for Expertise of Medicinal Application Products (Russia)
  • Spanish Ministry of Health
  • State Food and Drug Administration (SFDA)
  • The Cancer Centre Bahamas
  • The European Medicines Agency (EMA)
  • The German Generics Association Pro Generika
  • UCAB (The Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health
  • Washington Legal Foundation
  • World Health Organization (WHO)
Back to Top